Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Zeneca Inc., a wholly-owned subsidiary of the UK-based Zeneca Group PLC (NYSE: ZEN), filed suit against Eli Lilly & Co. (NYSE: LLY) in U.S. District Court for the Southern District of New York to stop Lilly's promotion of EVISTA(R) (raloxifene HCl). The suit seeks to, among other things, force Eli Lilly to cease its campaign aimed at misleading physicians and patients that EVISTA has been proven to reduce the incidence of breast cancer. In fact, EVISTA has been approved solely for the prevention of osteoporosis and, according to the FDA, "the effectiveness of raloxifene in reducing the risk of breast cancer has not been established." According to Zeneca, NOLVADEX is the only drug that has been proven effective for the reduction of the incidence of breast cancer in high risk women.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.